Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lowered its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 13.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 912,999 shares of the biopharmaceutical company's stock after selling 144,391 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.77% of Catalyst Pharmaceuticals worth $19,054,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CPRX. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth $27,000. Farther Finance Advisors LLC lifted its position in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $65,000. KBC Group NV increased its position in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $104,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock traded up $0.59 during trading hours on Friday, reaching $24.37. 988,043 shares of the stock were exchanged, compared to its average volume of 1,108,755. The business's fifty day moving average is $23.16 and its two-hundred day moving average is $22.45. The firm has a market capitalization of $2.97 billion, a P/E ratio of 20.65, a P/E/G ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.16.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This represents a 25.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 44,000 shares of the firm's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the sale, the insider now directly owns 68,873 shares in the company, valued at $1,627,468.99. This trade represents a 38.98% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 351,879 shares of company stock valued at $8,214,815. Insiders own 10.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CPRX. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Robert W. Baird raised their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Stephens reiterated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.